Drug intelligence / Profile preview

RSLV-125

Development stage: Discontinued
Lead developer: Resolve Therapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

**RSLV-125** is an antibody-like fusion protein developed by Resolve Therapeutics that inhibits the upstream interferon-alpha pathway to address chronic activation in autoimmune diseases. It represents a novel approach by targeting a proximal step in the inflammatory cascade, specifically designed to block interferon-alpha production, with primary focus on **systemic lupus erythematosus (SLE)**. Initially licensed from the University of Washington, the program has been discontinued.[1][3][5][6]

Targets

IFN-α (Interferon alpha-7)

Beyond the preview

Go deeper on RSLV-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSLV-125.

Explore the full profile